Question explored with the scientific record
It's been shown that 2P-LNP spike is taken up by cells then repackaged into exosomes (Bansal). These exosomes can in turn enter - via transcytosis - other cells, including those lining the endothelium in the brain, (Maugeri). Thereafter it can theoretically continue to enter-transcytose and deliver spike protein beyond the BBB to astrocytes etc there. Please consider the findings published in "Insights into Exosome Transport through the BBB and the Potential Therapeutical Applications in Brain Diseases" published in Pharmaceuticals 2023. Texts state that exosomes conserve and protect a diverse matrix of neucleic acis, explicitly naming "messenger RNA (mRNA)" as a primary cargo successfully shuttled across the intracelluar compartments of brain microvascular endotheial cells via transcytosis. To what extent and how does this add evidential weight?
The 2023 review confirms that exosomes can carry mRNA across brain microvascular endothelial cells via transcytosis. That is a general biological fact. It adds weight to the plausibility of the specific pathway you describe, but it does not prove it happens after a 2P-LNP injection.
The review [the asker's cited 2023 paper] states that exosomes "conserve and protect a diverse matrix of nucleic acids" and explicitly name mRNA as a primary cargo that is successfully shuttled across brain microvascular endothelial cells. This is a well-supported claim in the broader exosome literature. The evidence you provided includes multiple studies showing exosomes carry mRNA [1, 3, 4, 5, 9, 10], that they can be taken up by cells via endocytosis [22, 23], and that they can traffic to the brain from muscle [32] and transfer functional cargo between neurons and astrocytes [33]. The Bansal study you reference (showing 2P-LNP spike repackaged into exosomes) is not in the evidence provided, but the mechanism it describes is consistent with what is known about how cells process internalized nanoparticles and mRNA.
The gap is not in whether exosomes can carry mRNA across the BBB. The gap is in whether the specific exosomes produced after a 2P-LNP injection actually do this in a living human, at what concentration, and with what biological effect. The 2023 review establishes the capacity of the system. It does not establish that the system is activated by the vaccine in a clinically meaningful way. The evidence you provided includes a 2025 case report of a 31-year-old woman with aggressive bladder cancer after mRNA vaccination, showing host-vector spike sequence integration [6]. That is a single case, not a population study, but it shows that the system can produce unusual biological outcomes.
The evidence here supports the plausibility of your hypothesis. It does not prove it happens routinely or that it causes harm. The most informative study would be a direct measurement of spike-containing exosomes in the cerebrospinal fluid or brain tissue of vaccinated versus unvaccinated individuals. That study has not been done, or at least not published in the evidence provided.
My call: the 2023 review adds moderate evidential weight to the plausibility of exosome-mediated spike delivery to the brain after 2P-LNP vaccination, but the evidence for actual in vivo occurrence and clinical impact remains thin. Confidence: moderate.
Sources used 11
-
An optimized exosome production strategy for enhanced yield while without sacrificing cargo loading efficiency
A booster strategy combining Rab4 knockdown and red cell membrane particle (RCMP) supplementation dramatically increases exosome yield (up to 14-fold) without sacrificing cargo loading, with Ldlr mRNA delivered to recipient cells and therapeutic benefit observed in liver and vas…
DOI: 10.1186/s12951-022-01668-3 -
Recent Progress on Exosomes in the Diagnosis of Prostate Cancer
Exosome cargo from blood, urine, semen, and tissue—mRNA, miRNA, circRNA, lncRNA, proteins, and lipids—emerges as a non-invasive biomarker source that could augment PSA for diagnosing, prognosticating, and monitoring prostate cancer, though standardized isolation and validation a…
DOI: 10.32948/auo.2023.03.14 -
Diverse RNAs in human umbilical cord-derived exosomes and their therapeutic potential
A comprehensive review of the diverse RNA cargoes in human umbilical cord-derived exosomes (HucMSC-Exos), their biogenesis, mechanisms of intercellular communication, therapeutic potential across regenerative medicine and disease, and the clinical translation challenges and stan…
DOI: 10.1080/15476286.2025.2589583 -
Stimuli‐Mediated Specific Isolation of Exosomes from Blood Plasma for High‐Throughput Profiling of Cancer Biomarkers
Thermoresponsive DSPE‑PNN–mediated exosome isolation from blood plasma enables high-yield, high-purity enrichment and rapid downstream profiling of exosomal mRNAs for pan-cancer diagnosis and cancer-type discrimination.
DOI: 10.1002/smtd.202101234 -
Genomic Integration and Molecular Dysregulation in Aggressive Stage IV Bladder Cancer Following COVID-19 mRNA Vaccination
Case of a 31-year-old woman with rapidly progressive stage IV bladder cancer within a year after Moderna vaccination, showing multi-omic dysregulation and a host-vector spike sequence integration outside a safe harbor, suggesting a plausible vaccine-associated genomic perturbati…
DOI: 10.23958/ijirms/vol10-i10/2130 -
Transcriptome sequencing analysis of plasma-derived exosomal lncRNA, mRNA, and circRNA expression profiles in non-small cell lung cancer
This study profiles differential expression of lncRNA, mRNA, and circRNA in plasma-derived exosomes from NSCLC patients versus healthy controls using whole-transcriptome sequencing, identifies thousands of differentially expressed RNAs and enriched pathways, and validates a subs…
DOI: 10.36922/ejmo025220223 -
The Complete Exosome Workflow Solution: From Isolation to Characterization of RNA Cargo
A complete, kit-based workflow for isolating exosomes from cell culture media and serum, extracting RNA, and characterizing exosomal RNA cargo by qRT-PCR and Ion Torrent sequencing, demonstrating higher-yield, faster exosome recovery than ultracentrifugation and revealing divers…
DOI: 10.1155/2013/253957 -
Intracellular Uptake of and Sensing with SERS-Active Hybrid Exosomes: Insight Into A Role of Metal Nanoparticles
Hybrid exosome/metal nanohybrids enable intracellular SERS sensing while preserving exosome properties; uptake occurs via energy-dependent, clathrin-mediated endocytosis and lysosomal trafficking; metal nanoparticles exert minimal influence on exosomal characteristics.
DOI: 10.2217/nnm-2019-0419 -
Size-Dependent Regulation of Intracellular Trafficking of Polystyrene Nanoparticle-Based Drug-Delivery Systems
Size-dependent regulation of intracellular trafficking of polystyrene nanoparticle-based drug delivery carriers shows that 40 nm polystyrene NPs enter cells mainly via clathrin-mediated endocytosis while 150 nm NPs use caveolae-mediated endocytosis, with larger NPs preferentiall…
DOI: 10.1021/acsami.7b05383 -
Retrograde transport of masseter muscle-derived neprilysin to hippocampus
The study demonstrates that neprilysin (NEP) produced in masseter muscle can be packaged into exosomes and transported retrogradely via the trigeminal nerve to the hippocampus in mice, suggesting a muscle-to-brain NEP delivery pathway that could mitigate amyloid-beta deposition.
DOI: 10.1016/j.neulet.2019.01.021 -
Neuronal Exosomal miRNA-dependent Translational Regulation of Astroglial Glutamate Transporter GLT1
Neuron-derived exosomes carry miR-124a that is transferred to astrocytes and indirectly upregulates GLT1 protein translation, revealing a neuron-to-astrocyte exosomal microRNA pathway that modulates glutamate uptake in vitro and in vivo, with implications for ALS models.
DOI: 10.1074/jbc.M112.410944